Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03476330 · ClinicalTrials.gov registry record · Phase 2
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
A Phase 2 study of Squamous Cell Carcinoma and Fanconi Anemia, sponsored by Children's Hospital Medical Center, Cincinnati.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT03476330 is a Phase 2 study of Squamous Cell Carcinoma and Fanconi Anemia that is active but no longer recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 48 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03476330, a Phase 2 study of Squamous Cell Carcinoma and Fanconi Anemia, is active but no longer recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Improved transplant outcomes are modifying the natural history of Fanconi Anemia. Improved transplant survival, no radiation exposure, and almost no GVHD increases the importance of addressing later SCC even further. The investigators hypothesize that quercetin will prevent or delay the development of SCC and associated complications, there by ameliorating or delaying the need for potentially lethal treatment with chemotherapy and/or radiation therapy for the same. Funding Source - FDA Office of Orphan Products Development (OOPD)
Conditions Studied
Interventions
- DRUG Quercetin (dietary supplement)
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03476330
The ClinicalTrials.gov registry entry for NCT03476330 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (53% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Quercetin (dietary supplement) is the first listed.
NCT03476330 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03476330 about?
NCT03476330 is a clinical study titled "Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia". Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Improved transplant outcomes are modifying the na...
What is the current status of trial NCT03476330?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2018-05-08. Estimated completion is 2026-03.
What conditions does trial NCT03476330 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Fanconi Anemia.
What interventions are being tested in trial NCT03476330?
The interventions under investigation include: Quercetin (dietary supplement) (DRUG).
Who is sponsoring clinical trial NCT03476330?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03476330 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.